Biomea Fusion IncNASDAQ:BMEA
- LAST PRICE11.2300
- TODAY'S CHANGE (%)-0.6100 (-5.1520%)
- Bid / Lots11.2200/ 4
- Ask / Lots11.2600/ 4
- Open / Previous Close11.8000 / 11.8400
- Day Range
- 52 Week Range
- Volume172,655
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BMEA |
|---|---|---|
| 09:32 ET | 5620 | 11.68 |
| 09:34 ET | 2987 | 11.74 |
| 09:36 ET | 950 | 11.69 |
| 09:38 ET | 3370 | 11.725 |
| 09:39 ET | 1961 | 11.62 |
| 09:41 ET | 1381 | 11.68 |
| 09:43 ET | 443 | 11.63 |
| 09:45 ET | 1600 | 11.58 |
| 09:48 ET | 550 | 11.56 |
| 09:50 ET | 351 | 11.51 |
| 09:52 ET | 777 | 11.53 |
| 09:54 ET | 100 | 11.47 |
| 09:56 ET | 1800 | 11.51 |
| 09:57 ET | 300 | 11.54 |
| 10:03 ET | 1105 | 11.59 |
| 10:06 ET | 325 | 11.58 |
| 10:08 ET | 758 | 11.6 |
| 10:10 ET | 1014 | 11.58 |
| 10:12 ET | 14243 | 11.68 |
| 10:14 ET | 576 | 11.72 |
| 10:15 ET | 1854 | 11.8 |
| 10:17 ET | 444 | 11.79 |
| 10:19 ET | 757 | 11.83 |
| 10:21 ET | 1535 | 11.85 |
| 10:24 ET | 1727 | 11.81 |
| 10:26 ET | 1104 | 11.75 |
| 10:28 ET | 2600 | 11.68 |
| 10:30 ET | 100 | 11.68 |
| 10:32 ET | 200 | 11.68 |
| 10:35 ET | 200 | 11.69 |
| 10:37 ET | 500 | 11.72 |
| 10:39 ET | 1166 | 11.64 |
| 10:42 ET | 400 | 11.595 |
| 10:44 ET | 300 | 11.6 |
| 10:46 ET | 100 | 11.56 |
| 10:48 ET | 1600 | 11.665 |
| 10:50 ET | 495 | 11.68 |
| 10:51 ET | 2994 | 11.63 |
| 10:53 ET | 400 | 11.665 |
| 10:55 ET | 443 | 11.62 |
| 10:57 ET | 1000 | 11.59 |
| 11:00 ET | 1300 | 11.57 |
| 11:04 ET | 366 | 11.65 |
| 11:06 ET | 1864 | 11.64 |
| 11:08 ET | 300 | 11.66 |
| 11:09 ET | 100 | 11.63 |
| 11:11 ET | 300 | 11.6633 |
| 11:13 ET | 300 | 11.65 |
| 11:15 ET | 100 | 11.67 |
| 11:18 ET | 383 | 11.71 |
| 11:20 ET | 505 | 11.68 |
| 11:22 ET | 707 | 11.66 |
| 11:24 ET | 1142 | 11.61 |
| 11:26 ET | 1100 | 11.6 |
| 11:27 ET | 100 | 11.63 |
| 11:29 ET | 300 | 11.59 |
| 11:33 ET | 100 | 11.59 |
| 11:36 ET | 600 | 11.59 |
| 11:38 ET | 300 | 11.555 |
| 11:40 ET | 200 | 11.57 |
| 11:42 ET | 100 | 11.59 |
| 11:44 ET | 300 | 11.58 |
| 11:45 ET | 599 | 11.55 |
| 11:47 ET | 100 | 11.54 |
| 11:49 ET | 100 | 11.52 |
| 11:54 ET | 957 | 11.54 |
| 11:56 ET | 216 | 11.55 |
| 11:58 ET | 200 | 11.52 |
| 12:03 ET | 1637 | 11.41 |
| 12:05 ET | 600 | 11.43 |
| 12:07 ET | 200 | 11.42 |
| 12:09 ET | 1000 | 11.43 |
| 12:12 ET | 450 | 11.41 |
| 12:14 ET | 555 | 11.4 |
| 12:16 ET | 100 | 11.4 |
| 12:18 ET | 6160 | 11.39 |
| 12:20 ET | 750 | 11.4 |
| 12:21 ET | 300 | 11.37 |
| 12:23 ET | 100 | 11.36 |
| 12:25 ET | 334 | 11.36 |
| 12:27 ET | 200 | 11.35 |
| 12:30 ET | 1099 | 11.34 |
| 12:32 ET | 500 | 11.325 |
| 12:34 ET | 3740 | 11.31 |
| 12:36 ET | 300 | 11.29 |
| 12:38 ET | 500 | 11.3 |
| 12:39 ET | 600 | 11.28 |
| 12:41 ET | 1200 | 11.3 |
| 12:43 ET | 300 | 11.31 |
| 12:45 ET | 539 | 11.3 |
| 12:48 ET | 720 | 11.29 |
| 12:50 ET | 100 | 11.26 |
| 12:52 ET | 999 | 11.31 |
| 12:54 ET | 100 | 11.3 |
| 12:56 ET | 600 | 11.285 |
| 12:57 ET | 400 | 11.3 |
| 12:59 ET | 800 | 11.29 |
| 01:01 ET | 1827 | 11.31 |
| 01:03 ET | 586 | 11.32 |
| 01:06 ET | 200 | 11.32 |
| 01:08 ET | 430 | 11.31 |
| 01:10 ET | 423 | 11.29 |
| 01:14 ET | 1050 | 11.31 |
| 01:15 ET | 819 | 11.31 |
| 01:21 ET | 2070 | 11.34 |
| 01:24 ET | 1186 | 11.35 |
| 01:26 ET | 664 | 11.3799 |
| 01:32 ET | 100 | 11.385 |
| 01:42 ET | 800 | 11.36 |
| 01:44 ET | 558 | 11.3301 |
| 01:48 ET | 1351 | 11.32 |
| 01:51 ET | 737 | 11.29 |
| 01:55 ET | 100 | 11.28 |
| 01:57 ET | 5687 | 11.24 |
| 02:00 ET | 2167 | 11.26 |
| 02:02 ET | 902 | 11.28 |
| 02:04 ET | 500 | 11.25 |
| 02:06 ET | 200 | 11.24 |
| 02:08 ET | 100 | 11.23 |
Jun 3, 2024
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Monday Jun 03, 2024 by Dow Jones
4:05PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
DJ Biomea Fusion Is Maintained at Outperform by Oppenheimer, from 10:34AM ET on Thursday May 30, 2024 by Dow Jones
10:34AM ET on Thursday May 30, 2024 by Dow JonesBiomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes, from 9:12AM ET on Thursday May 30, 2024 by Dow Jones
9:12AM ET on Thursday May 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Biomea Fusion Inc | 378.1M | -3.2x | --- |
enGene Holdings Inc | 387.6M | -1.7x | --- |
Terns Pharmaceuticals Inc | 388.7M | -5.7x | --- |
LENZ Therapeutics Inc | 390.4M | -0.9x | --- |
Aura Biosciences Inc | 364.1M | -4.0x | --- |
Fibrobiologics Inc | 398.5M | -8.8x | --- |
Company Information
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Contact Information
- Headquarters
- 900 Middlefield Road, 4Th FloorREDWOOD CITY, CA, United States 94063
- Phone
- 650-980-9099
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Thomas Butler
- President, Co-Founder, Chief Operating Officer, Director
- Rainer Erdtmann
- Chief Financial Officer
- Franco Valle
- Chief Medical Officer
- Juan Fras
- Chief Development Officer
- Steve Morris
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $378.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
